Kybernin P

Antithrombin III, the active ingredient in Kybernin P, is an antithrombin concentrate presented as an intravenous solution for intravenous use. It is used to treat bleeding in patients with congenital antithrombin deficiency and to prevent thromboembolic events in surgical settings. GNH USA supplies Kybernin P as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Kybernin P is an antithrombin concentrate indicated for disorders of coagulation where antithrombin activity is deficient or where thrombosis risk is high.

Congenital antithrombin deficiency: restores antithrombin activity to control bleeding. Surgical patients at risk of thrombosis: prevents postoperative thromboembolic events. Cardiopulmonary bypass procedures: maintains anticoagulant balance during extracorporeal circulation.

Common Side Effects: - Infusion‑related reactions such as flushing, chills, or fever. - Mild headache or dizziness. - Nausea or mild gastrointestinal discomfort. - Transient hypotension during administration.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions. - Unexpected severe bleeding. - Thrombotic events despite therapy. - Hemolysis or disseminated intravascular coagulation (DIC).

Kybernin P requires careful clinical monitoring and adherence to safety guidelines. - Dose adjustment: individualize based on measured antithrombin activity levels. - Renal impairment: monitor renal function and adjust dosing as needed. - Pregnancy: use only when the potential benefit justifies the potential risk to the fetus. - Bleeding risk: assess patient’s baseline bleeding tendency before infusion. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kybernin P may interact with other agents that affect coagulation.

Major Interactions (Avoid): - Heparin: additive anticoagulant effect can cause severe bleeding. - Other anticoagulants (warfarin, direct oral anticoagulants): increased risk of hemorrhage.

Moderate Interactions (Monitor Closely): - Antifibrinolytics (e.g., tranexamic acid): may reduce the efficacy of antithrombin therapy. - Platelet inhibitors (aspirin, clopidogrel): monitor for enhanced bleeding tendencies.